Portfolio company
Code Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops non-viral genetic medicine delivery platforms and therapies for patients with rare and prevalent genetic diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Stridebio
This company develops engineered viral vectors and gene therapies for patients with rare genetic diseases.
Spot Biosystems
This company develops non-viral gene therapy delivery platforms using extracellular vesicles to treat genetic diseases for pharmaceutical partners and healthcare providers.
Gene Therapy Delivery Methods
This company develops viral and non-viral vector platforms to provide genetic material delivery solutions for biotechnology firms and healthcare providers.
LogicBio
This company develops gene editing and delivery platforms to provide one-time treatments for patients with serious, early-onset rare genetic diseases.
Immitra Bio
This company develops an in-vivo gene editing platform to provide off-the-shelf curative treatments for patients with rare genetic diseases.
SonoThera™
This company develops an ultrasound-guided non-viral platform to deliver genetic medicines for patients with chronic and rare diseases.
Anjarium BioSciences
This company develops non-viral gene therapies and synthetic DNA vectors for patients with genetic diseases and life sciences researchers.
Kodikaz Therapeutics
Kodikaz Therapeutics develops a cell-specific non-viral delivery platform for targeted gene therapies to treat various cancers for patients and healthcare providers.